SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lönn Lars 1956)
 

Sökning: WFRF:(Lönn Lars 1956) > Growth hormone redu...

Growth hormone reduces inflammation in postmenopausal women with abdominal obesity: a 12-month, randomized, placebo-controlled trial.

Franco Ramos, Celina, 1956 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine
Andersson, Björn, 1953 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
Lönn, Lars, 1956 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
visa fler...
Bengtsson, Bengt-Åke, 1944 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
Svensson, Johan, 1964 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
Johannsson, Gudmundur, 1960 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
visa färre...
 (creator_code:org_t)
The Endocrine Society, 2007
2007
Engelska.
Ingår i: The Journal of clinical endocrinology and metabolism. - : The Endocrine Society. - 0021-972X .- 1945-7197. ; 92:7, s. 2644-7
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • CONTEXT: Abdominal obesity is associated with low GH secretion, elevated circulating markers of inflammation, and increased risk of cardiovascular disease. OBJECTIVE: The objective was to study the effect of GH treatment on inflammatory markers and vascular adhesion molecules in postmenopausal women with abdominal obesity. DESIGN: Forty women aged 51-63 yr received GH (0.67 mg/d) in a randomized, double-blind, placebo-controlled, 12-month trial. Measurements of inflammatory markers [highly sensitive C-reactive protein (CRP), IL-6, and amyloid polypeptideA] and markers of endothelial dysfunction (soluble E-selectin, vascular adhesion molecule-1, intercellular molecule-1, and matrix metalloproteinase-9) were performed at baseline and after 6 and 12 months of treatment. RESULTS: After 12 months, the mean IGF sd score was 0.9 +/- 1.5 and -0.8 +/- 0.6 in the GH and placebo groups, respectively. GH treatment reduced CRP and IL-6 levels compared with placebo (P = 0.03 and P = 0.05, respectively), whereas the markers of endothelial dysfunction were unaffected. Within the GH-treated group, a reduction was shown in CRP (4.3 +/- 4 to 3.0 +/- 3 mg/liter; P < 0.05) and in IL-6 (4.4 +/- 2 to 3.3 +/- 2 ng/liter; P < 0.01). In the GH-treated group, the decrease in CRP and IL-6 correlated with a reduction in visceral adipose tissue (r = 0.7, P < 0.001 and r = 0.5, P < 0.05, respectively). CONCLUSION: GH treatment in postmenopausal women with abdominal obesity reduced serum markers of systemic inflammation. Circulating markers of endothelial dysfunction were unaffected by treatment.

Nyckelord

Abdominal Fat
Aged
C-Reactive Protein
metabolism
Endothelium
Vascular
drug effects
immunology
Female
Human Growth Hormone
therapeutic use
Humans
Inflammation
blood
drug therapy
Interleukin-6
blood
Middle Aged
Obesity
drug therapy
immunology
metabolism
Placebos
Postmenopause
Serum Amyloid A Protein
metabolism

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy